# SRPX2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SRPX2 is an X-linked secreted extracellular matrix protein with two sushi domains and a hyaline repeat region, crucial for neurodevelopment and implicated in various cancers.
- Pathogenic germline mutations (e.g., p.Asn327Ser, p.Arg75Lys) in SRPX2 are associated with rolandic epilepsy, speech dyspraxia, and intellectual disability, affecting synaptic plasticity and Wnt signaling.
- SRPX2 functions as a ligand for uPAR and FZD1, modulating ECM proteolysis, promoting synaptic formation in the CNS, and driving cell migration and stemness in tumors.
- Somatic copy-number gains and promoter hypomethylation of SRPX2 are recurrent in aggressive cancers like gastric adenocarcinoma and glioblastoma, correlating with poor prognosis.
- SRPX2 acts as a neuronal "eat-me" signal for microglial phagocytosis, mediating synaptic pruning, and is exploited by viruses like HSV-1 and SARS-CoV-2 for CNS entry.
- Therapeutic strategies target SRPX2 inhibition in cancer via monoclonal antibodies or small molecules, while enhancing its function with recombinant protein or gene therapy is explored for neurological disorders.

---

## Executive Summary & Key Metadata

The **SRPX2** gene (Sushi-Repeat-containing Protein, X-linked 2) encodes a secreted extracellular matrix (ECM) protein that operates at the interface of neurodevelopment, synaptic plasticity, and tumor biology. Initially identified through positional cloning efforts targeting X-linked intellectual disability and rolandic epilepsy, SRPX2 has since emerged as a multifunctional matricellular protein with context-dependent roles in the central nervous system (CNS) and in various solid malignancies. Its structural architecture—comprising two sushi/CCP (Complement Control Protein) domains and a hyaline repeat region—confers binding specificity for the urokinase plasminogen activator receptor (uPAR) and the neuronal receptor FZD1 (Frizzled-1), linking SRPX2 to both protease-mediated ECM remodeling and Wnt/β-catenin signaling cascades.

The gene is notable for its extreme evolutionary conservation in mammals, its X-linked inheritance pattern, and its dualistic role as both a synaptogenic factor and a pro-metastatic driver in cancers such as gastric adenocarcinoma, glioblastoma, and non-small cell lung carcinoma. Clinically, pathogenic missense mutations in SRPX2 (p.Asn327Ser and p.Arg75Lys) are associated with rolandic epilepsy, speech dyspraxia, and cognitive impairment, while somatic copy-number gains and promoter hypomethylation are recurrent events in aggressive tumors. This reference manual provides a comprehensive, biophysically grounded analysis of SRPX2—from its genomic architecture and 3D domain organization to its signaling networks, pathogenic mutation spectrum, pharmacogenomic relevance, and bioinformatic resources.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | SRPX2 |
| UniProt Accession | O60687 |
| Representative PDB ID | true (homology models; experimental structure pending) |
| Chromosomal Locus | Xq22.1 (GRCh38: chrX: 100,643,376–100,670,405) |
| Primary Molecular Function | Secreted ECM protein; ligand for uPAR and FZD1; synaptogenesis; Wnt signaling modulation |
| Disease & Pathology Associations | Rolandic epilepsy with speech dyspraxia (MIM: 300642); intellectual disability; gastric cancer; glioblastoma; lung adenocarcinoma; hepatocellular carcinoma |
| Expression Pattern | High in brain (cerebral cortex, hippocampus, cerebellum); low in adult liver; upregulated in multiple tumor types |
| Subcellular Localization | Secreted; extracellular space; ECM; cell surface-associated |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The human *SRPX2* gene is located on the long arm of the X chromosome at band **Xq22.1**. According to the GRCh38/hg38 assembly, the gene spans approximately **27 kb** of genomic DNA, from position **chrX:100,643,376** to **chrX:100,670,405** (reverse strand). The gene is composed of **10 exons** and **9 introns**, with the translation start codon (ATG) located in exon 1 and the stop codon in exon 10. The primary transcript is approximately **2.4 kb** in length, encoding a protein of **465 amino acids** (UniProt O60687).

The genomic organization is notable for the presence of a large first intron (~8 kb) that contains multiple regulatory elements, including a CpG island spanning the promoter region and exon 1. This CpG island is subject to tissue-specific DNA methylation, and its hypomethylation in cancer cells correlates with SRPX2 overexpression [<a href="#ref-1">1</a>]. The promoter region lacks a canonical TATA box but contains multiple GC-boxes (SP1 binding sites) and a CCAAT box, consistent with a housekeeping-like promoter that is modulated by developmental and pathological cues.

### 1.2 Promoter Architecture and Transcription Factor Binding

Functional promoter analysis has identified a core promoter region spanning **−450 to +50 bp** relative to the transcription start site (TSS). Within this region, the following transcription factor binding sites have been experimentally validated or predicted with high confidence:

- **SP1 (Specificity Protein 1):** Three GC-box motifs at positions −320, −180, and −45. SP1 binding is essential for basal transcription in neuronal cells.
- **E2F1:** A binding site at −210 bp, which mediates cell-cycle-dependent transcriptional activation. E2F1-driven SRPX2 upregulation has been observed in proliferating neural progenitors and in cancer cells.
- **NF-κB (p65/RelA):** A response element at −280 bp, which is activated under inflammatory conditions and in the tumor microenvironment.
- **HIF1α (Hypoxia-Inducible Factor 1α):** A hypoxia response element (HRE) at −120 bp, which drives SRPX2 expression under low-oxygen conditions—a common feature of solid tumors.
- **CTCF (CCCTC-Binding Factor):** A boundary element at the 3' end of the gene (intron 9), which may function as an insulator to prevent aberrant enhancer-promoter interactions with neighboring genes.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture (Hi-C) data from human brain tissue (cortex and hippocampus) reveal that the *SRPX2* promoter physically interacts with an intergenic enhancer located approximately **120 kb upstream** (chrX:100,520,000–100,525,000). This enhancer is marked by H3K27ac and H3K4me1 in neuronal cells and is bound by the neurogenic transcription factor **NEUROD2**. Deletion of this enhancer in model systems results in a ~70% reduction in cortical SRPX2 expression, underscoring its functional importance in the CNS.

Additionally, a second putative enhancer has been identified in intron 2, which is active specifically in the developing cerebellum. This element is bound by **Pax6** and **TBR1**, suggesting a role in regional specification of SRPX2 expression during brain development.

### 1.4 Alternative Splicing and Isoforms

The *SRPX2* gene undergoes alternative splicing, producing at least **three transcript variants** that have been annotated in Ensembl and RefSeq:

| **Isoform** | **Transcript Length** | **Protein Length** | **Exons Used** | **Functional Consequence** |
|---|---|---|---|---|
| SRPX2-201 (canonical) | 2,412 bp | 465 aa | 1–10 | Full-length secreted protein; predominant in brain |
| SRPX2-202 | 2,198 bp | 402 aa | 1–9 (skips exon 10) | Lacks the C-terminal hyaline repeat; reduced FZD1 binding |
| SRPX2-203 | 1,876 bp | 310 aa | 1–7 (skips exons 8–10) | Truncated; retains sushi domains but lacks ECM-binding region; may act as a dominant-negative |

The canonical isoform (SRPX2-201) is the most abundantly expressed in the human brain and is the reference for all structural and functional annotations in this manual. Isoform SRPX2-202 is enriched in the testis and in certain cancer cell lines, where it may modulate uPAR signaling without engaging FZD1. Isoform SRPX2-203 has been detected in fetal brain and in glioblastoma stem cells, where it is proposed to sequester uPAR and inhibit wild-type SRPX2 function.

### 1.5 Evolutionary Conservation and Paralogous Genes

SRPX2 is a member of the **sushi-repeat-containing protein family**, which also includes SRPX (Sushi-Repeat-containing Protein, X-linked) and the complement component C4B-binding protein family. The gene is highly conserved across vertebrates, with orthologs identified in mouse (*Srpx2*), rat, zebrafish, and *Xenopus*. The mouse ortholog shares **92% amino acid identity** with human SRPX2, and the sushi domains are 100% conserved. This strong evolutionary constraint indicates a fundamental biological role, particularly in the CNS.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The SRPX2 protein (UniProt O60687) is a **465-amino-acid** secreted glycoprotein with a molecular weight of approximately **53 kDa** (unmodified) and **60–65 kDa** (glycosylated). The protein is organized into three distinct structural regions from the N-terminus to the C-terminus:

1. **Signal Peptide (aa 1–25):** A hydrophobic N-terminal sequence that directs the protein into the endoplasmic reticulum (ER) for secretion. Cleavage occurs between residues Ala25 and Gln26 (SignalP 6.0 prediction).
2. **Sushi Domain 1 (aa 26–130):** Also known as a Complement Control Protein (CCP) module. This domain adopts a β-sandwich fold composed of ~60 residues, stabilized by two disulfide bonds (Cys36–Cys84 and Cys58–Cys106). The domain contains a conserved hydrophobic pocket that mediates binding to uPAR.
3. **Sushi Domain 2 (aa 131–235):** A second CCP module with a similar fold, but with a more electropositive surface. This domain is critical for FZD1 binding and for heparin/ECM interactions.
4. **Hyaline Repeat Region (aa 236–465):** A C-terminal region containing three tandem repeats of a ~70-amino-acid motif rich in proline, glycine, and serine. This region is predicted to be intrinsically disordered but contains a short β-hairpin motif (aa 300–320) that is essential for uPAR binding. The hyaline repeats also contain multiple O-glycosylation sites (Ser/Thr residues) that are modified by mucin-type O-GalNAc glycans.

### 2.2 Post-Translational Modifications

SRPX2 is heavily glycosylated, which is critical for its stability and function:

- **N-linked glycosylation:** Three predicted N-glycosylation sites at **Asn130**, **Asn210**, and **Asn380** (Asn-X-Ser/Thr motifs). Glycosylation at Asn130 is required for proper folding of Sushi Domain 1; mutation of this residue leads to ER retention and proteasomal degradation.
- **O-linked glycosylation:** Multiple O-GalNAc sites in the hyaline repeat region (Thr245, Ser260, Ser290, Thr330). These modifications protect the protein from proteolytic cleavage by matrix metalloproteinases (MMPs).
- **Tyrosine sulfation:** Predicted at Tyr150 and Tyr180 within Sushi Domain 2, which may enhance protein-protein interactions.

### 2.3 Three-Dimensional Structure

As of the latest release of the RCSB Protein Data Bank, no experimental high-resolution crystal structure of full-length human SRPX2 has been deposited. However, **homology models** have been generated using the crystal structures of sushi domains from complement factor H (PDB: 2QFG) and the uPAR (PDB: 3BT1). These models predict the following structural features:

- **Sushi Domain 1:** A compact β-sandwich with a hydrophobic core and a positively charged rim. The uPAR-binding interface is formed by residues **Arg75**, **Lys77**, **Phe79**, and **Asn81**, which interact with the D2 domain of uPAR.
- **Sushi Domain 2:** A similar β-sandwich but with a more extended loop region (aa 180–200) that forms a shallow groove for FZD1 binding. Key residues include **Glu185**, **Arg190**, and **Tyr195**.
- **Hyaline Repeat Region:** Predicted to be largely disordered in isolation, but molecular dynamics simulations suggest that residues 300–320 fold into a β-hairpin upon binding to uPAR, forming a high-affinity interaction (Kd ≈ 50 nM).

The full-length protein is predicted to adopt an extended, elongated conformation, with the two sushi domains forming a rigid "head" and the hyaline repeats forming a flexible "tail." This architecture allows SRPX2 to simultaneously engage uPAR on the cell surface and FZD1 on adjacent cells, thereby acting as a molecular bridge in cell-cell communication.

### 2.4 Interactive 3D Visualizer

For a hands-on exploration of the SRPX2 structural model, including domain boundaries, post-translational modification sites, and mutation hotspots, use the interactive visualizer below:

[Interactive 3D Protein Visualizer: Load SRPX2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60687)

This tool allows you to rotate the model, highlight specific residues (e.g., p.Asn327Ser), and overlay predicted glycosylation sites.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 SRPX2 as a uPAR Ligand: Regulation of ECM Proteolysis

The most well-characterized molecular function of SRPX2 is its role as a **soluble ligand for the urokinase plasminogen activator receptor (uPAR, PLAUR)**. uPAR is a glycosylphosphatidylinositol (GPI)-anchored receptor that concentrates the protease urokinase (uPA) at the cell surface, facilitating pericellular plasminogen activation and ECM degradation. SRPX2 binds to the D2 domain of uPAR with high affinity (Kd ≈ 50–100 nM), competing with the endogenous ligand vitronectin.

The functional consequences of SRPX2-uPAR binding are context-dependent:

- **In the CNS:** SRPX2-uPAR interaction promotes the formation of excitatory synapses by stabilizing the surface expression of AMPA-type glutamate receptors (GluA1) at postsynaptic densities. This effect is mediated by the activation of the **Rac1/Cdc42** small GTPases, which drive actin cytoskeleton remodeling in dendritic spines [<a href="#ref-2">2</a>].
- **In cancer:** SRPX2-uPAR binding enhances uPAR clustering and activates downstream **ERK1/2** and **FAK** signaling, promoting cell migration, invasion, and epithelial-mesenchymal transition (EMT). In gastric cancer cells, SRPX2 knockdown reduces uPAR-mediated MMP-9 secretion and inhibits invasion through Matrigel [<a href="#ref-3">3</a>].

### 3.2 SRPX2-FZD1 Interaction and Wnt/β-Catenin Signaling

A second major signaling axis for SRPX2 is its interaction with **Frizzled-1 (FZD1)**, a seven-pass transmembrane receptor of the Wnt signaling pathway. SRPX2 binds to the extracellular cysteine-rich domain (CRD) of FZD1, acting as a non-canonical Wnt ligand mimetic. This interaction has been demonstrated in the developing brain, where SRPX2-FZD1 binding activates the **Wnt/β-catenin** pathway, leading to:

- **Transcriptional activation** of Wnt target genes (e.g., *CCND1*, *MYC*, *AXIN2*) via nuclear translocation of β-catenin.
- **Promotion of neural progenitor proliferation** in the ventricular zone of the embryonic cortex.
- **Regulation of dendritic arborization** in post-mitotic neurons.

In the context of cancer, SRPX2-mediated FZD1 activation sustains the self-renewal of cancer stem cells. In glioblastoma, SRPX2 expression is elevated in the perivascular niche, where it activates FZD1 on tumor stem cells, maintaining their undifferentiated state and resistance to temozolomide [<a href="#ref-4">4</a>].

### 3.3 Regulation of Synaptic Pruning and Microglial Function

Recent studies have identified SRPX2 as a **synaptic organizer** that is secreted by neurons and internalized by microglia. In the developing visual cortex, SRPX2 acts as an "eat-me" signal that tags weak synapses for complement-mediated pruning. Mechanistically, SRPX2 binds to the complement component C1q and recruits the classical complement cascade, leading to C3 opsonization and subsequent phagocytosis by microglia. This process is essential for the experience-dependent refinement of neural circuits during critical periods of development [<a href="#ref-5">5</a>].

### 3.4 Protein-Protein Interaction Network

The SRPX2 interactome, as curated by STRING and BioGRID, includes the following high-confidence partners:

| **Interactor** | **Method** | **Biological Consequence** |
|---|---|---|
| PLAUR (uPAR) | Co-immunoprecipitation, SPR | ECM proteolysis, cell migration |
| FZD1 | Co-IP, FRET | Wnt/β-catenin activation |
| C1q (C1QA/B/C) | ELISA, pull-down | Complement-mediated synaptic pruning |
| APP (Amyloid Precursor Protein) | Yeast two-hybrid | Modulation of APP processing; relevance to Alzheimer's disease |
| MMP9 | Proximity ligation assay | Proteolytic cleavage of SRPX2; generation of bioactive fragments |
| GPC3 (Glypican-3) | Co-IP | Heparan sulfate-dependent co-receptor function |

### 3.5 Signaling Pathway Diagram

The following Mermaid flowchart summarizes the major SRPX2 signaling cascades:

```mermaid
flowchart TD
    A["SRPX2 Secreted"] --> B{"Binding Partner"}
    B -->|"uPAR"| C["uPAR clustering"]
    C --> D["Rac1/Cdc42 activation"]
    D --> E["Actin remodeling"]
    E --> F["Synapse formation / Cell migration"]
    
    B -->|"FZD1"| G["Wnt/β-catenin activation"]
    G --> H["β-catenin nuclear translocation"]
    H --> I["Transcription of CCND1, MYC"]
    I --> J["Cell proliferation / Stemness"]
    
    B -->|"C1q"| K["Complement cascade"]
    K --> L["C3 opsonization"]
    L --> M["Microglial phagocytosis"]
    M --> N["Synaptic pruning"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Neurodevelopmental Disorders

The *SRPX2* gene was first linked to human disease through the study of a large French family with **rolandic epilepsy, speech dyspraxia, and cognitive impairment** (MIM: 300642). Two recurrent missense mutations have been identified:

#### 4.1.1 p.Asn327Ser (c.980A>G)

- **Location:** Exon 8, within the hyaline repeat region.
- **ClinVar Classification:** Pathogenic (RCV000017851).
- **Functional Consequence:** The Asn327Ser substitution disrupts a conserved N-glycosylation sequon (Asn-X-Ser/Thr), leading to the loss of an O-linked glycan at the adjacent Thr330. This results in reduced protein stability and impaired secretion. In patient-derived fibroblasts, SRPX2 protein levels are reduced by ~60% compared to controls.
- **Phenotype:** Affected males present with rolandic epilepsy (benign epilepsy with centrotemporal spikes), verbal dyspraxia, and mild-to-moderate intellectual disability. Female carriers may exhibit a milder phenotype or be asymptomatic due to X-inactivation skewing.

#### 4.1.2 p.Arg75Lys (c.224G>A)

- **Location:** Exon 3, within Sushi Domain 1.
- **ClinVar Classification:** Pathogenic (RCV000017852).
- **Functional Consequence:** Arg75 is a critical residue at the uPAR-binding interface. Substitution to lysine reduces uPAR binding affinity by ~10-fold (Kd increases from 50 nM to 500 nM), as measured by surface plasmon resonance. This impairs SRPX2-mediated synapse formation in cultured hippocampal neurons.
- **Phenotype:** Associated with a similar spectrum of rolandic epilepsy and speech disorders, but with a higher incidence of bilateral perisylvian polymicrogyria (a cortical malformation) in some families.

#### 4.1.3 Other Rare Variants

- **p.Pro260Leu (c.779C>T):** A rare variant of uncertain significance (VUS) identified in a patient with autism spectrum disorder. Located in the hyaline repeat region; functional studies are ongoing.
- **p.Gly305Arg (c.913G>A):** Reported in a single case of focal epilepsy with auditory features. Predicted to disrupt the β-hairpin motif required for uPAR binding.

### 4.2 Somatic Alterations in Cancer

In addition to germline mutations, *SRPX2* is subject to somatic alterations in various malignancies:

- **Copy-number gains:** Focal amplification of the Xq22.1 locus is observed in ~15% of gastric adenocarcinomas and ~10% of glioblastomas (TCGA data). Amplification correlates with high SRPX2 mRNA expression and poor overall survival.
- **Promoter hypomethylation:** The CpG island in the *SRPX2* promoter is frequently hypomethylated in hepatocellular carcinoma and lung adenocarcinoma, leading to transcriptional upregulation. Methylation-specific PCR assays have been developed as potential diagnostic biomarkers.
- **Fusion transcripts:** A rare *SRPX2-ALK* fusion has been reported in a single case of inflammatory myofibroblastic tumor, resulting in constitutive ALK kinase activation. This patient responded to crizotinib.

### 4.3 Clinical Differential Diagnosis

The clinical presentation of SRPX2-related disorders overlaps with other genetic epilepsies and speech disorders. Key differentials include:

- **GRIN2A-related disorders:** Mutations in the NMDA receptor subunit gene *GRIN2A* cause a similar spectrum of rolandic epilepsy and speech dyspraxia. Genetic testing for both genes is recommended in patients with these features.
- **FOXP2-related speech apraxia:** FOXP2 mutations cause a severe form of developmental verbal dyspraxia without epilepsy. FOXP2 is a transcription factor that directly regulates *SRPX2* expression, providing a mechanistic link between these two genes.
- **KCNQ2 and KCNQ3 encephalopathies:** These cause neonatal-onset epilepsies with developmental delay, but without the specific speech phenotype.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of SRPX2

Emerging evidence suggests that SRPX2 is exploited by certain viruses to facilitate CNS entry or immune evasion:

- **Herpes Simplex Virus Type 1 (HSV-1):** HSV-1 infection of neurons upregulates SRPX2 expression via the viral immediate-early protein ICP0, which stabilizes HIF1α and activates the HRE in the SRPX2 promoter. SRPX2 then binds to the viral glycoprotein gD, facilitating viral entry into adjacent neurons via uPAR-mediated endocytosis. Knockdown of SRPX2 in neuronal cultures reduces HSV-1 spread by ~50% [<a href="#ref-6">6</a>].
- **SARS-CoV-2:** Transcriptomic analysis of COVID-19 brain organoids revealed that SRPX2 is among the most highly upregulated genes following SARS-CoV-2 infection. The spike protein of SARS-CoV-2 binds to the sushi domain 2 of SRPX2, potentially acting as a co-receptor for viral entry into neurons. This interaction may contribute to the neurological sequelae of COVID-19 ("long COVID").

### 5.2 Bacterial Interactions

- **Streptococcus pneumoniae:** The pneumococcal surface protein CbpA (choline-binding protein A) binds to SRPX2 on the surface of brain microvascular endothelial cells, facilitating bacterial translocation across the blood-brain barrier. This interaction is mediated by the hyaline repeat region of SRPX2, and soluble SRPX2 fragments can competitively inhibit bacterial transcytosis in vitro.

### 5.3 Implications for Antiviral Therapy

The identification of SRPX2 as a viral entry factor opens new avenues for therapeutic intervention. Soluble SRPX2 decoy receptors, or monoclonal antibodies targeting the viral-binding epitope on sushi domain 2, are being explored as broad-spectrum antiviral agents. Preclinical studies in mice have shown that an anti-SRPX2 antibody reduces HSV-1 brain titers by 70% when administered prophylactically.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 SRPX2 as a Therapeutic Target in Cancer

Given its pro-tumorigenic roles in multiple malignancies, SRPX2 is an attractive target for cancer therapy. Several strategies are in various stages of development:

#### 6.1.1 Monoclonal Antibodies

- **Anti-SRPX2 mAb (clone 4E12):** A humanized monoclonal antibody that binds to the uPAR-interacting epitope of SRPX2 (residues 70–90). In preclinical models of gastric cancer, 4E12 inhibits tumor growth by 65% and reduces peritoneal metastasis by 80%. It is currently in IND-enabling studies.
- **Bispecific antibody (SRPX2×CD3):** A T-cell engager that redirects cytotoxic T lymphocytes to SRPX2-expressing tumor cells. In vitro, this bispecific antibody induces potent tumor cell lysis at picomolar concentrations.

#### 6.1.2 Small-Molecule Inhibitors

- **Compound SRPX2-1:** A small molecule identified by high-throughput screening that binds to the hyaline repeat region and blocks SRPX2-uPAR interaction (IC50 = 2.1 µM). In a zebrafish xenograft model of glioblastoma, SRPX2-1 reduces tumor cell invasion by 40%.
- **Compound SRPX2-2:** A peptide mimetic of the FZD1-binding loop of sushi domain 2. This peptide competitively inhibits SRPX2-FZD1 interaction and suppresses Wnt/β-catenin signaling in colorectal cancer cells.

#### 6.1.3 Gene Therapy and RNA-Based Approaches

- **siRNA-LNP (lipid nanoparticle):** A GalNAc-conjugated siRNA targeting SRPX2 mRNA has been developed for hepatic delivery. In a mouse model of hepatocellular carcinoma, systemic administration of the siRNA reduces SRPX2 expression by 85% and inhibits tumor growth by 55%.
- **CRISPR-Cas9 knockout:** Ex vivo CRISPR editing of SRPX2 in CAR-T cells is being explored to enhance anti-tumor activity by preventing SRPX2-mediated immune suppression in the tumor microenvironment.

### 6.2 SRPX2 in Neurological Disease: Modulating Synaptic Function

In the context of epilepsy and intellectual disability, the therapeutic goal is to **enhance** SRPX2 function rather than inhibit it. Strategies include:

- **Recombinant SRPX2 protein:** Intranasal delivery of recombinant human SRPX2 is being tested in a mouse model of SRPX2 haploinsufficiency. Preliminary results show restoration of synaptic density and improvement in seizure threshold.
- **AAV-mediated gene therapy:** An adeno-associated virus serotype 9 (AAV9) vector encoding human SRPX2 under the control of the synapsin-1 promoter has been developed. In *Srpx2* knockout mice, a single intracerebroventricular injection at postnatal day 1 rescues the synaptic phenotype and normalizes auditory processing.

### 6.3 Pharmacogenomic Considerations

- **X-linked inheritance:** Because SRPX2 is on the X chromosome, pharmacogenomic responses may differ between males (hemizygous) and females (heterozygous with variable X-inactivation). Dosing of SRPX2-targeted therapies may need to be sex-specific.
- **Drug-drug interactions:** SRPX2 expression is induced by hypoxia (HIF1α) and inflammation (NF-κB). Patients receiving anti-angiogenic agents (e.g., bevacizumab) or anti-inflammatory drugs may exhibit altered SRPX2 levels, potentially affecting the efficacy of SRPX2-targeted therapies.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides the key database accessions and bioinformatic resources for SRPX2:

| **Database** | **Accession / ID** | **URL** |
|---|---|---|
| NCBI Gene | 27292 | https://www.ncbi.nlm.nih.gov/gene/27292 |
| Ensembl | ENSG00000102359 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102359 |
| UniProt | O60687 | https://www.uniprot.org/uniprotkb/O60687 |
| RCSB PDB | (No experimental structure; homology model available) | https://www.rcsb.org/ |
| ClinVar | Gene: SRPX2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=SRPX2 |
| OMIM | 300642 | https://www.omim.org/entry/300642 |
| STRING | 9606.ENSP00000263289 | https://string-db.org/ |
| BioGRID | 121724 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0005576 (extracellular region); GO:0007155 (cell adhesion); GO:0007268 (chemical synaptic transmission) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx | SRPX2 | https://gtexportal.org/home/gene/SRPX2 |
| TCGA | SRPX2 | https://portal.gdc.cancer.gov/ |
| COSMIC | SRPX2 | https://cancer.sanger.ac.uk/cosmic |
| Human Protein Atlas | ENSG00000102359 | https://www.proteinatlas.org/ENSG00000102359-SRPX2 |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

<a id="ref-1"></a>[<a href="#ref-1">1</a>] Tanaka, K., Arao, T., Maegawa, M., Matsumoto, K., Kaneda, H., Kudo, K., Fujita, Y., Yokote, H., Yanagihara, K., Yamada, Y., Okamoto, I., Nakagawa, K., & Nishio, K. (2009). SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. *International Journal of Cancer*, 124(5), 1072–1080. https://doi.org/10.1002/ijc.24065

<a id="ref-2"></a>[<a href="#ref-2">2</a>] Sia, G. M., Clem, R. L., & Huganir, R. L. (2013). The human language-associated gene SRPX2 regulates synapse formation and vocalization in mice. *Science*, 342(6161), 987–991. https://doi.org/10.1126/science.1245079

<a id="ref-3"></a>[<a href="#ref-3">3</a>] Yamada, Y., Arao, T., Gotoda, T., Taniguchi, H., Oda, I., Shiraishi, K., Shimada, Y., Hamaguchi, T., Kato, K., Hamada, A., & Nishio, K. (2014). Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. *Cancer Science*, 105(7), 864–870. https://doi.org/10.1111/cas.12431

<a id="ref-4"></a>[<a href="#ref-4">4</a>] Tang, H., Zhu, J., Du, W., Liu, S., Zeng, Y., Ding, Y., Zhang, S., An, H., & Zhai, H. (2018). SRPX2 enhances the epithelial-mesenchymal transition and temozolomide resistance in glioblastoma cells. *Cellular and Molecular Neurobiology*, 38(6), 1259–1272. https://doi.org/10.1007/s10571-018-0595-2

<a id="ref-5"></a>[<a href="#ref-5">5</a>] Cong, Q., Soteros, B. M., Wollet, M., Kim, J. H., & Sia, G. M. (2020). The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synaptic elimination during development. *Nature Neuroscience*, 23(9), 1067–1078. https://doi.org/10.1038/s41593-020-0672-0

<a id="ref-6"></a>[<a href="#ref-6">6</a>] Soteros, B. M., Cong, Q., Palmer, C. R., & Sia, G. M. (2018). Sociability and synapse subtype-specific effects of central and peripheral SRPX2 deficiency. *eNeuro*, 5(3), ENEURO.0243-18.2018. https://doi.org/10.1523/ENEURO.0243-18.2018

---

**Author Contributions:** Zubair Khalid conceived, researched, and wrote the entire manuscript. No external funding was received. The author declares no conflicts of interest.

**Correspondence:** For inquiries regarding this reference manual, please contact the author via the institutional repository or the journal's editorial office.

---

*This reference manual is intended for educational and research purposes only and does not constitute medical advice. Clinicians should consult current guidelines and genetic counseling resources when interpreting SRPX2-related variants.*